Notice: This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends ANCN vs. DRRX, CARM, VYNE, RVPH, NXTC, AEON, MRKR, TRVN, LEXX, and HILSShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include DURECT (DRRX), Carisma Therapeutics (CARM), VYNE Therapeutics (VYNE), Reviva Pharmaceuticals (RVPH), NextCure (NXTC), AEON Biopharma (AEON), Marker Therapeutics (MRKR), Trevena (TRVN), Lexaria Bioscience (LEXX), and Hillstream BioPharma (HILS). These companies are all part of the "medical" sector. Anchiano Therapeutics vs. DURECT Carisma Therapeutics VYNE Therapeutics Reviva Pharmaceuticals NextCure AEON Biopharma Marker Therapeutics Trevena Lexaria Bioscience Hillstream BioPharma DURECT (NASDAQ:DRRX) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Does the media refer more to DRRX or ANCN? In the previous week, DURECT had 1 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 1 mentions for DURECT and 0 mentions for Anchiano Therapeutics. DURECT's average media sentiment score of 0.00 equaled Anchiano Therapeutics'average media sentiment score. Company Overall Sentiment DURECT Neutral Anchiano Therapeutics Neutral Which has more risk & volatility, DRRX or ANCN? DURECT has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Do institutionals & insiders hold more shares of DRRX or ANCN? 28.0% of DURECT shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 3.2% of DURECT shares are owned by insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, DRRX or ANCN? Anchiano Therapeutics has lower revenue, but higher earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$8.55M4.86-$27.62M-$0.61-2.20Anchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.40 Do analysts rate DRRX or ANCN? DURECT currently has a consensus price target of $21.00, suggesting a potential upside of 1,467.16%. Given DURECT's higher possible upside, equities analysts clearly believe DURECT is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community believe in DRRX or ANCN? DURECT received 258 more outperform votes than Anchiano Therapeutics when rated by MarketBeat users. However, 65.91% of users gave Anchiano Therapeutics an outperform vote while only 64.36% of users gave DURECT an outperform vote. CompanyUnderperformOutperformDURECTOutperform Votes31664.36% Underperform Votes17535.64% Anchiano TherapeuticsOutperform Votes5865.91% Underperform Votes3034.09% Is DRRX or ANCN more profitable? Anchiano Therapeutics has a net margin of 0.00% compared to DURECT's net margin of -187.80%. Anchiano Therapeutics' return on equity of 36.08% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-187.80% -261.43% -66.98% Anchiano Therapeutics N/A 36.08%27.40% SummaryDURECT beats Anchiano Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.24M$7.03B$5.40B$8.51BDividend YieldN/A7.96%5.16%4.14%P/E Ratio9.209.59113.0915.15Price / SalesN/A386.181,478.8493.55Price / CashN/A47.3239.8334.03Price / Book0.695.324.645.01Net Income-$27.12M$153.56M$119.13M$225.46M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$1.38-2.8%N/A+89.0%$10.24MN/A9.2016Gap UpDRRXDURECT2.7703 of 5 stars$1.35-7.5%$21.00+1,455.6%-55.0%$41.90M$8.41M-2.2180Positive NewsCARMCarisma Therapeutics2.6054 of 5 stars$1.00-1.0%$7.00+600.0%-65.6%$41.55M$20.71M-0.5620Analyst UpgradeNews CoverageGap UpVYNEVYNE Therapeutics2.8705 of 5 stars$2.73+1.5%$5.75+110.6%-11.4%$40.27M$486,000.00-1.0630RVPHReviva Pharmaceuticals1.9824 of 5 stars$1.16-1.7%$15.50+1,242.0%-77.2%$38.62MN/A-0.895News CoverageGap UpNXTCNextCure3.888 of 5 stars$1.35-3.6%$6.00+344.4%+24.3%$37.77MN/A-0.6290Upcoming EarningsPositive NewsAEONAEON Biopharma1.6588 of 5 stars$0.94-4.1%$5.00+431.9%-83.0%$36.78MN/A0.005Gap DownMRKRMarker Therapeutics3.5493 of 5 stars$4.07-0.5%$19.00+366.8%+28.9%$36.32M$3.31M0.0060Gap DownTRVNTrevena1.3684 of 5 stars$1.98-1.0%$125.00+6,213.1%-87.1%$36.32M$443,000.00-0.0440Gap UpLEXXLexaria Bioscience2.7008 of 5 stars$2.27-3.8%$11.00+384.6%+60.0%$35.91M$411,019.00-5.167Short Interest ↓HILSHillstream BioPharmaN/A$2.03+2.5%N/A+1,734.0%$35.73MN/A-2.821Gap Down Related Companies and Tools Related Companies DRRX Alternatives CARM Alternatives VYNE Alternatives RVPH Alternatives NXTC Alternatives AEON Alternatives MRKR Alternatives TRVN Alternatives LEXX Alternatives HILS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANCN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
